Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 2/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.49 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.49 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 5/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223237 | 0.81 | ALDH1A1 (0.49) | KMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL5226670 | 0.78 | ENPP2 (0.56) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5222423 | 0.76 | F10 (0.56) | F10POLB | |
| SCHEMBL5223733 | 0.74 | F10 (0.60) | F10KMT2AMEN1POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5224970 | 0.74 | F10 (0.55) | F10POLB | |
| SCHEMBL14456742 | 0.72 | MEN1 (0.60) | KMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL6172046 | 0.72 | RXFP2 (0.54) | F10 | |
| SCHEMBL1554165 | 0.71 | F10 (0.55) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15853659 | 0.71 | HIF1A (0.69) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| Hydrochloric Acid SCHEMBL5225364 | 0.71 | F10 (0.59) | F10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014962-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2007-06-27 | — | — | EP | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | PRKAB2 4227/4885PRKAG1 4246/4885PRKAA2 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.